Notably, high expression of ATP5F1B in primary UM is significantly associated with reduced progression-free survival and reduced OS, and patients with disomy 3 and low ATP5F1B expression have a reduced risk of metastatic disease [18]. This evidence concerns the gene ATP5F1B and metastatic neoplasm.